Elanco Animal Health Incorporated (ELAN)
USD 11.73
(-4.71%)
USD 11.73
(-4.71%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.73 Billion USD | 12.81% |
| 2022 | 1.53 Billion USD | 12.02% |
| 2021 | 1.37 Billion USD | -13.0% |
| 2020 | 1.57 Billion USD | 50.2% |
| 2019 | 1.05 Billion USD | 4.64% |
| 2018 | 1 Billion USD | -5.48% |
| 2017 | 1.06 Billion USD | 21.32% |
| 2016 | 875.6 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 1.63 Billion USD | -5.59% |
| 2024 Q2 | 1.61 Billion USD | -1.65% |
| 2023 FY | 1.73 Billion USD | 12.81% |
| 2023 Q1 | 1.59 Billion USD | 3.77% |
| 2023 Q2 | 1.69 Billion USD | 5.89% |
| 2023 Q3 | 1.69 Billion USD | 0.0% |
| 2023 Q4 | 1.73 Billion USD | 2.66% |
| 2022 Q2 | 1.33 Billion USD | -0.82% |
| 2022 FY | 1.53 Billion USD | 12.02% |
| 2022 Q4 | 1.53 Billion USD | 14.78% |
| 2022 Q3 | 1.34 Billion USD | 0.45% |
| 2022 Q1 | 1.34 Billion USD | -2.04% |
| 2021 Q2 | 1.45 Billion USD | 1.83% |
| 2021 Q3 | 1.38 Billion USD | -4.62% |
| 2021 FY | 1.37 Billion USD | -13.0% |
| 2021 Q4 | 1.37 Billion USD | -0.72% |
| 2021 Q1 | 1.42 Billion USD | -9.76% |
| 2020 Q1 | 1.01 Billion USD | -3.02% |
| 2020 Q2 | 1.06 Billion USD | 4.54% |
| 2020 Q3 | 1.59 Billion USD | 49.92% |
| 2020 FY | 1.57 Billion USD | 50.2% |
| 2020 Q4 | 1.57 Billion USD | -1.19% |
| 2019 Q4 | 1.05 Billion USD | -1.68% |
| 2019 Q1 | 1.03 Billion USD | 3.13% |
| 2019 Q3 | 1.06 Billion USD | 1.48% |
| 2019 FY | 1.05 Billion USD | 4.64% |
| 2019 Q2 | 1.05 Billion USD | 1.7% |
| 2018 Q1 | - USD | -100.0% |
| 2018 FY | 1 Billion USD | -5.48% |
| 2018 Q4 | 1 Billion USD | -0.46% |
| 2018 Q3 | 1 Billion USD | 0.31% |
| 2018 Q2 | 1 Billion USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | 1.06 Billion USD | 0.0% |
| 2017 FY | 1.06 Billion USD | 21.32% |
| 2016 FY | 875.6 Million USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 581.38 Million USD | -198.426% |
| Bausch Health Companies Inc. | 1.54 Billion USD | -12.37% |
| Catalent, Inc. | 574 Million USD | -202.265% |
| Emergent BioSolutions Inc. | 328.9 Million USD | -427.516% |
| Perrigo Company plc | 1.14 Billion USD | -52.073% |
| Teva Pharmaceutical Industries Limited | 4.02 Billion USD | 56.852% |
| Zoetis Inc. | 2.56 Billion USD | 32.332% |